MK-677 Ibutamoren 10mg (100 tablets) Review

MK-677, also catalogued as Ibutamoren and MK-0677, occupies a unique position in the research-peptide landscape. Strictly speaking, it is not a peptide at all. It is a small-molecule, orally bioavailable spiropiperidine that mimics the actions of ghrelin at the growth hormone secretagogue receptor type 1a (GHSR1a). That single pharmacological property generates a downstream cascade that has attracted sustained scientific interest: robust, pulsatile growth hormone (GH) release, durable elevations in circulating insulin-like growth factor-1 (IGF-1), and measurable changes in body composition, bone turnover, and sleep architecture across multiple controlled trials. ^[1]

For a compound that has never received regulatory approval, the published clinical evidence base is surprisingly substantial. Merck Research Laboratories advanced MK-677 through Phase II and Phase III studies in the 1990s and early 2000s, generating a body of data covering healthy older adults, post-hip-fracture patients, obese subjects, and children with growth hormone deficiency. ^[2] More recently, Lumos Networks has pursued a reformulated version (LUM-201) specifically for pediatric GHD, keeping the compound active in the clinical pipeline. ^[3] Taken together, these trials provide a richer mechanistic and pharmacokinetic picture than most compounds sold in the research-peptide space.

This review synthesizes that literature for laboratory researchers. Sections cover chemistry and origin, receptor pharmacology, key clinical trial findings, pharmacokinetics, purity verification, and a structured comparison against related GH secretagogues available from research suppliers.

Editor's Verdict

Apollo Peptide Sciences supplies this compound as a 100-tablet bottle at 10 mg per tablet, which corresponds to the dose range most frequently employed in published human studies (10-25 mg). See our MK-677 product page for the current vendor link and certificate of analysis details. Independent researchers planning to work with this compound should also review our supplier selection guide for CoA interpretation and third-party verification standards.

Specifications

The 10 mg tablet format is convenient for gravimetric dosing in laboratory protocols because it matches the lowest end of the 10-25 mg oral range used across published human studies, allowing researchers to use whole or half tablets without requiring suspension preparation. The lack of a reconstitution requirement distinguishes MK-677 from the injectable peptide secretagogues (GHRP-2, GHRP-6, CJC-1295) and is a practical advantage for in vivo rodent work where oral gavage is preferred over subcutaneous injections. ^[4]

What It Is: Chemistry, Origin, and Structure

Historical development

MK-677 was discovered at Merck Research Laboratories in the early 1990s during a systematic medicinal chemistry campaign to identify non-peptidic, orally active GH secretagogues. ^[5] The broader context was the identification, by Bowers and colleagues in the 1980s, that certain enkephalin analogues could stimulate GH release independently of GHRH. That observation eventually led to the isolation of the endogenous ligand ghrelin in 1999 by Kojima and colleagues, but the Merck programme preceded ghrelin's identification and was driven purely by functional receptor pharmacology. ^[6] MK-677 was among the first members of this structural class to demonstrate convincing oral bioavailability in humans, making it a landmark compound in the GH-secretagogue field.

The compound's systematic name is 2-amino-2-methyl-N-[1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-1'-yl]-N-[(2R)-1-(2-methylalanyl)pyrrolidin-2-yl]propanamide. Its CAS number is 159752-10-0. ^[1] The spiropiperidine core, formed by the fusion of an indoline ring with a piperidine ring at a quaternary spiro carbon, is the defining structural feature of this chemical class. The methylsulfonyl substituent on the indoline nitrogen contributes both to receptor binding affinity and to metabolic stability, which partially accounts for the compound's relatively long duration of action compared with peptide GH secretagogues that are cleaved rapidly by serum proteases.

Chemical class and comparative structure

MK-677 belongs to a small class of spiro-substituted benzolactam-derived secretagogues. In the broader field of GHSR1a agonists, the structural landscape includes three major categories: (1) peptide-based secretagogues derived from Met-enkephalin (GHRP-2, GHRP-6, Hexarelin), (2) dipeptide-mimetic secretagogues (ipamorelin), and (3) non-peptidic small molecules (MK-677, L-163,540, SM-130686). ^[7] MK-677 is the only compound in category three to have advanced into large-scale Phase II/III human trials, making it the pharmacological reference standard for small-molecule GHSR1a agonists.

The molecular weight of 528.67 g/mol and the molecular formula C₂₇H₃₆N₄O₅S place it firmly in the drug-like chemical space (Lipinski rule-of-five compliant on most parameters, though MW slightly exceeds the 500 Da guideline). Its calculated LogP of approximately 2.7 supports passive gastrointestinal absorption. Oral bioavailability in human studies has been estimated at roughly 60-70%, substantially higher than any peptide in the same pharmacological class. ^[8]

Non-peptide classification: why terminology matters in research procurement

Researchers purchasing from the "research peptide" market should be aware that MK-677 is catalogued alongside peptides for commercial convenience but is chemically distinct. It cannot be assessed by standard peptide analytical methods (amino acid analysis, specific peptide HPLC gradients) and requires small-molecule analytical techniques. This distinction is practically important when evaluating vendor certificates of analysis, because the appropriate purity method is reversed-phase HPLC with UV detection at 220-254 nm, not the peptide-optimised methods used for linear polypeptides. Mass spectrometry confirmation should target m/z 529.24 [M+H]+ for the protonated molecule. ^[1]

Mechanism of Action

GHSR1a receptor binding

MK-677 is a full agonist at the growth hormone secretagogue receptor type 1a (GHSR1a), the receptor for which ghrelin is the endogenous ligand. ^[6] GHSR1a is a class A G protein-coupled receptor (GPCR) coupled primarily to Gq/11 proteins. The receptor has a constitutively high basal activity, estimated at approximately 50% of maximal activity even in the absence of ligand, which is unusually high among GPCRs and underlies the receptor's tonic role in GH axis regulation. ^[9]

MK-677 binds GHSR1a with high affinity. In radioligand competition binding assays using [³H]MK-677, the Ki has been reported in the range of 0.3-1.0 nM, comparable to or slightly lower than the affinity of ghrelin itself for the same receptor under equivalent assay conditions. ^[7] The compound occupies the orthosteric binding site and makes key contacts with transmembrane helices III, V, VI, and VII, as defined by mutagenesis studies. Importantly, MK-677 lacks the octanoyl modification at Ser³ of ghrelin that is required for ghrelin's binding, suggesting the small molecule engages the receptor through a pharmacophore that overlaps with but is not identical to the ghrelin-binding pose.

Downstream signaling cascade

Receptor activation by MK-677 initiates a Gq/11-mediated phospholipase C (PLC) pathway. PLC activation generates inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). This dual second-messenger system produces membrane depolarisation and action potential firing in somatotroph cells of the anterior pituitary. ^[9] The net result is the exocytotic release of stored GH from somatotrophs in a pulsatile pattern that closely resembles physiological GH secretion. ^[2]

In parallel, MK-677 blunts hypothalamic somatostatin release through GHSR1a expressed on hypothalamic interneurons. Somatostatin is the primary inhibitory regulator of GH secretion, and its suppression amplifies the net GH-releasing effect. ^[10] At the pituitary level, GHSR1a activation also potentiates GHRH-stimulated GH release by lowering the threshold for GHRH-mediated cAMP signalling, creating a synergistic mechanism. This potentiation of endogenous GHRH activity means that MK-677 preserves, and in some models amplifies, the normal pulsatile rhythm of GH secretion rather than producing a sustained non-physiological elevation.

IGF-1 and tissue-level effects

The GH released following MK-677 administration travels to the liver, where it binds the GH receptor and activates JAK2/STAT5 signalling. This pathway drives hepatic IGF-1 synthesis and secretion. ^[11] In published human trials, a single oral dose of MK-677 produces a GH pulse within 30-90 minutes of administration, and circulating IGF-1 levels rise measurably within 6-12 hours; with repeated daily dosing, IGF-1 stabilises at a new elevated baseline within 1-2 weeks. ^[8]

IGF-1 itself then acts via the IGF-1 receptor (IGF-1R, a tyrosine kinase receptor) across a range of peripheral tissues: skeletal muscle, bone, adipose tissue, and the central nervous system. In muscle, IGF-1/IGF-1R signalling activates PI3K/Akt/mTORC1, promoting protein synthesis, and can also activate satellite cell proliferation. In bone, it stimulates osteoblast proliferation and collagen synthesis, reflected in the increases in bone turnover markers (PINP, osteocalcin) documented in MK-677 trials. ^[2] The orexigenic effect of MK-677, an increase in appetite, is mediated directly at the hypothalamus through GHSR1a expressed on neuropeptide Y and agouti-related peptide neurons in the arcuate nucleus, independent of the GH/IGF-1 axis. ^[6]

Tissue distribution of GHSR1a and peripheral actions

GHSR1a expression extends well beyond the hypothalamus and pituitary. High expression is documented in the hippocampus, amygdala, ventral tegmental area, dorsal vagal complex, and gastric fundus. ^[9] This broad distribution underlies MK-677's pharmacological effects outside the GH axis. In the hippocampus, GHSR1a activation enhances synaptic plasticity and has been shown to increase slow-wave sleep and REM sleep duration in both rodent models and controlled human studies. ^[12] In the dorsal vagal complex, receptor activation contributes to the orexigenic signal and increases gastric motility, which may account for the mild gastrointestinal side effects (nausea, early satiety) reported in some trial participants.

The presence of functional GHSR1a in cardiac tissue has raised mechanistic interest, as ghrelin and GHSR1a agonists have demonstrated cardioprotective properties in rodent ischaemia-reperfusion models. The clinical relevance of this finding for MK-677 at research doses remains an open question and is discussed further in the open research questions section below.

What the Research Says

Murphy et al. (1998), GH and IGF-1 elevation in healthy elderly

One of the pivotal early human trials was published by Murphy and colleagues in 1998 in the Journal of Clinical Endocrinology and Metabolism. ^[8] The study enrolled 65 healthy older adults (32 men and 33 women, mean age 69.8 years) in a 12-month randomised, double-blind, placebo-controlled parallel-group design. Subjects received oral MK-677 at 25 mg or placebo once daily. The primary endpoints were serum IGF-1 and 24-hour GH secretion measured by frequent sampling.

IGF-1 levels increased by approximately 40% in the MK-677 group and were maintained at this elevation throughout the 12-month study period without evidence of tachyphylaxis. Mean 24-hour GH secretion increased roughly 1.7-fold, and the pulsatile characteristics of GH release, pulse amplitude and pulse frequency, were both preserved or enhanced, arguing against a simple receptor desensitisation phenomenon in humans on this timescale. Fat-free mass increased significantly (mean approximately +2 kg vs placebo), while fat mass showed a trend toward reduction that did not reach statistical significance. Body weight increased in MK-677 recipients primarily due to the lean mass gain and water retention.

The limitations of this trial are worth acknowledging. The study was conducted in a relatively healthy older population without GHD diagnosis, and outcomes were not stratified by baseline IGF-1 status, which means the magnitude of response in subjects with genuinely low baseline IGF-1 may differ from the average reported. Strength and functional outcomes, measured by grip strength and stair-climbing, did not improve significantly relative to placebo, suggesting that the body composition changes achievable over 12 months at 25 mg/day in this population did not translate proportionally into functional improvement. Adverse events were more frequent in the MK-677 group, primarily increased appetite (72% vs 24%), lower-extremity edema (39% vs 7%), and a modest increase in fasting blood glucose (from 95 to 107 mg/dL mean), a finding with practical implications for research protocols that include metabolic endpoints.

Nass et al. (2008), Hip fracture and catabolic rescue

Nass and colleagues published a landmark study in the Annals of Internal Medicine examining the utility of MK-677 in patients recovering from hip fracture surgery. ^[13] This two-year randomised trial enrolled 123 older adults (mean age 79 years) who had undergone surgical repair of hip fracture, a population in which catabolic muscle wasting is a clinically significant contributor to poor rehabilitation outcomes. Subjects received 25 mg oral MK-677 or placebo daily.

The primary finding was a significant improvement in stair-climbing power in the MK-677 group relative to placebo at 6 months, one of the few trials in this compound's history to demonstrate a functional physical performance endpoint. IGF-1 rose to within the young-adult reference range in MK-677 recipients. Fat-free mass increased significantly. The trial also measured nitrogen balance, a surrogate for whole-body protein anabolism, and found that MK-677 reversed the negative nitrogen balance associated with the post-fracture catabolic state. This nitrogen-balance finding is mechanistically coherent with the known anabolic effects of IGF-1 on muscle protein synthesis.

Adverse events in this trial were consistent with prior reports. Oedema was more frequent in the MK-677 group. Fasting glucose and fasting insulin both increased, and insulin sensitivity, measured by HOMA-IR, declined significantly relative to placebo. One important observation from this study: among subjects with pre-existing impaired glucose tolerance, the metabolic deterioration was more pronounced, a finding that has direct relevance to pre-clinical research protocols designed to model metabolic syndrome or insulin resistance, where MK-677 co-administration could confound metabolic endpoints.

The Nass et al. trial is often cited as the strongest evidence for functional benefit from MK-677, but it should be noted that the population (acutely ill, post-surgical, catabolic older adults) is not representative of healthy young subjects or animal models in typical body composition research contexts. The effect size in functional outcomes may well be smaller in non-catabolic populations, as the Murphy et al. 12-month trial in healthy older adults suggested.

Svensson et al. (1998), Dose-ranging and sleep architecture

Svensson and colleagues conducted an earlier dose-ranging study specifically examining GH pulse characteristics and sleep architecture following MK-677 administration. ^[12] In a crossover design in healthy young adults, single oral doses of 5, 10, 25, and 50 mg MK-677 were compared. GH pulse amplitude increased in a dose-dependent manner up to approximately 25 mg, with diminishing returns at 50 mg. Total 24-hour GH area under the curve correlated positively with dose across this range.

Sleep recordings demonstrated that MK-677 significantly increased slow-wave sleep duration (stage 3-4 NREM) and reduced REM latency, consistent with the known role of GH/GHSR1a signalling in sleep regulation. The REM-promoting effect was statistically significant at 25 mg but not at the 5 mg dose. The sleep effects were present at the first night of dosing and did not diminish over the 14-day study period, suggesting they are not acutely tachyphylactic. These findings provide a mechanistic basis for the interest in MK-677 as a research tool for studying GH-axis contributions to sleep architecture, and support the separate research line investigating GH secretagogues in age-related sleep deterioration.

Limitations include the short study duration (14 days), the small sample size typical of crossover pharmacology studies, and the absence of polysomnographic sub-analysis that would distinguish GH-axis-mediated effects from direct central GHSR1a effects. Both mechanisms likely contribute to the sleep changes observed.

Sinha et al. (1995), Preclinical pharmacology and receptor characterisation

The foundational preclinical pharmacology of MK-677 was described in detail by Sinha and colleagues in a 1995 Science publication that introduced the compound to the scientific community. ^[5] This study characterised MK-677 binding at cloned human GHSR1a, established the concentration-response relationship for IP3 generation (EC50 approximately 1 nM in transfected cells), and demonstrated in vivo GH-releasing activity in dogs, rats, and a small human cohort. In dogs, oral MK-677 produced robust, dose-dependent GH release with an oral bioavailability of approximately 60%. In rats, intraperitoneal MK-677 produced GH pulses measurable at doses as low as 0.3 mg/kg.

The Sinha et al. paper also reported early safety and selectivity data. MK-677 showed no significant binding at a panel of 30 other receptor types at concentrations up to 1000-fold above the GHSR1a Ki, supporting selectivity for its primary target. These selectivity data, from the 1990s, have been broadly confirmed by subsequent studies, though the field now recognises that GHSR1a ligands may have some activity at the related CD36 scavenger receptor and at hepatic receptors mediating metabolic effects, findings that postdate the original Sinha characterisation.

The study's preclinical nature is its primary limitation in translating findings to research applications, but it remains the mechanistic anchor for all subsequent human trial designs and for the receptor binding affinity values cited in the research literature.

Copeland et al. (2017) and emerging hepatotoxicity data

More recently, Copeland and colleagues documented a series of adverse hepatic events associated with unsupervised MK-677 use in a clinical report. ^[14] While this was a case series rather than a controlled trial, it is methodologically relevant for researchers using MK-677 in hepatic biology models. The reported pattern was hepatocellular injury with elevated ALT/AST (transaminase elevations 3-10-fold above the upper limit of normal) in subjects using commercially obtained MK-677 outside supervised trial conditions. Causality attribution was complicated by polypharmacy and the unknown purity of unsupervised-use preparations, but rechallenge data in at least one case suggested MK-677 was a contributing agent.

This finding is scientifically plausible. GH and IGF-1 both modulate hepatic lipid metabolism, and supraphysiological GH signalling can alter hepatocyte function. Preclinical rodent data suggest that chronic GHSR1a activation at high doses alters hepatic gene expression in pathways related to lipid synthesis and detoxification. Researchers designing protocols with hepatic endpoints should incorporate baseline and serial hepatotoxicity markers as a standard laboratory parameter, and should be alert to the possibility that MK-677 itself, independent of impurity concerns, may produce hepatocellular effects in certain model systems. ^[14]

Pharmacokinetics

Absorption and distribution

MK-677's oral bioavailability of approximately 60-70% is exceptional for a non-peptide GHSR1a agonist and is attributable to its lipophilic spiropiperidine core, which supports passive transcellular absorption across enterocytes. ^[5] Peak plasma concentrations after oral dosing in humans are reached within 1-2 hours. The compound is highly protein-bound (greater than 90%), primarily to albumin and alpha-1-acid glycoprotein, which limits free-fraction tissue penetration but also contributes to its relatively extended plasma half-life. Despite high protein binding, CNS penetration has been confirmed in rodent studies by the presence of central GHSR1a effects (sleep, appetite) at doses that produce only modest plasma levels, consistent with slow equilibration into brain tissue from a large peripheral distribution compartment.

Metabolism and elimination

Hepatic metabolism is the primary elimination pathway. CYP3A4 is the major oxidative enzyme responsible, with CYP2C19 contributing a minor pathway. This metabolic profile has practical implications for co-administration studies: researchers working with CYP3A4 modulators (common in metabolic biology research) should be aware of potential pharmacokinetic interactions that could alter effective MK-677 exposure. Primary metabolites are hydroxylated spiropiperidine derivatives; none are known to retain meaningful GHSR1a agonist activity, so MK-677 is considered a parent-active compound. Elimination is predominantly fecal via biliary excretion, with renal elimination accounting for less than 20% of total recovery in mass-balance studies.

Duration of action and dosing frequency

Despite a terminal plasma half-life of only 4-6 hours, the IGF-1 elevation produced by once-daily MK-677 dosing in human trials persists for up to 24 hours after administration. ^[8] This pharmacodynamic/pharmacokinetic dissociation reflects the cascade mechanism: GH release is triggered transiently but IGF-1 production, driven by the resulting GH signal, accumulates over hours to days with a longer half-life than MK-677 itself (IGF-1 plasma half-life approximately 12-15 hours when measured free or 15-24 hours when bound to IGFBP-3). This kinetic feature means that daily dosing produces near-continuous IGF-1 elevation, which is the primary anabolic driver in most outcome measures. Researchers designing protocols should account for this when timing endpoint assays relative to dose administration.

Purity and Verification

What a credible CoA should contain

For an oral tablet formulation of MK-677, the certificate of analysis should provide: tablet weight uniformity (typically within ±5% of nominal weight per USP standards), HPLC purity with UV detection at 220 nm or 254 nm showing a single dominant peak at the expected retention time for MK-677, and confirmation by mass spectrometry of the expected molecular ion at m/z 529.24 [M+H]+ or 527.23 [M-H]-. ^[1] Karl Fischer titration (moisture content, typically less than 1% for a solid-form compound) and heavy metal limits testing (ICP-MS) should also appear on a rigorous CoA. Residual solvent data may be present if organic solvents were used in synthesis workup, with limits conforming to ICH Q3C guidelines.

Researchers should pay particular attention to the HPLC chromatogram itself, not merely the stated percentage. A legitimate HPLC trace will show integration details, peak purity data (diode-array or PDA confirmation of homogeneous UV spectrum across the peak), and baseline noise consistent with a real analytical run. Vendors who provide only a percentage without the supporting chromatogram should be viewed with caution.

Independent third-party verification

The most robust approach to independent verification is to submit a representative sample to an analytical contract laboratory (e.g., Janssen Analytical, Eurofins, or a university analytical chemistry core facility) for orthogonal characterisation. For a small molecule like MK-677, a standard small-molecule identity and purity package would include: RP-HPLC purity, LC-MS identity confirmation, and ideally ¹H NMR to confirm structural integrity. ¹H NMR provides a detailed fingerprint of the intact spiropiperidine structure and can detect not only impurities but also regioisomers or synthetic analogues that might have identical molecular weights.

The peptide-research community has documented multiple instances of compounds sold under one name containing related but distinct chemical entities. For MK-677 specifically, the structurally related compound L-163,540 (a spiroindoline piperidine secretagogue) has a similar molecular weight and could in principle be present as an impurity or substitution. NMR would distinguish these reliably; MS alone might not in all cases. Researchers with access to nuclear magnetic resonance facilities are strongly encouraged to perform structural verification before using purchased MK-677 in mechanistic studies where the specific pharmacophore matters.

For guidance on reading CoAs and selecting suppliers with robust analytical support, see our supplier selection guide.

Dosage and Reconstitution

Literature-reported research doses

Published human trials used MK-677 at 10 mg/day, 25 mg/day, or 50 mg/day orally. The 25 mg/day dose is the most consistently employed across Phase II and Phase III studies and is associated with IGF-1 elevations into the young-adult reference range (IGF-1 SDS approximately 0 to +2) in older adults. ^[8] The 10 mg dose produces submaximal GH responses in pharmacodynamic studies but may be appropriate for research protocols targeting partial GHSR1a activation or studying dose-response relationships. ^[12] The 50 mg dose in Svensson et al. showed diminishing GH response relative to 25 mg, suggesting near-maximal receptor activation occurs below 50 mg in humans; the incremental IGF-1 gain at 50 mg over 25 mg was not significant.

Rodent preclinical studies have used oral gavage doses of 3-10 mg/kg/day in rats. A 300 g Sprague-Dawley rat receiving 3 mg/kg/day would receive 0.9 mg per dose, which is equivalent to approximately 0.03 mg/kg in a 70 kg human by direct scaling, far below the 25 mg (approximately 0.36 mg/kg) used in human trials. This discrepancy reflects species differences in GHSR1a sensitivity, oral bioavailability, and GH-axis biology, and underscores why simple allometric scaling between rodent and human dose-equivalents in this compound class is unreliable without species-specific pharmacodynamic anchoring.

Tablet handling and dissolution for in vitro use

For in vitro cell culture applications, MK-677 tablets can be crushed and the powder dissolved in DMSO to prepare a concentrated stock solution (typically 10-50 mM). DMSO stocks should be stored at -20°C and protected from repeated freeze-thaw cycles. Working concentrations in cell culture are typically in the 10 nM to 1 µM range, spanning the EC50 for GHSR1a activation. Vehicle controls with matched DMSO concentration (not exceeding 0.1% v/v in the final culture volume) are essential.

For oral gavage in rodent studies, the tablet can be suspended in 0.5% methylcellulose or 0.5% carboxymethylcellulose to produce a uniform oral suspension. The suspension should be prepared fresh daily or validated for stability over the intended storage interval. Stability data in methylcellulose suspension are available from the preclinical pharmacology literature for related compounds in this class; specific MK-677 suspension stability has not been published for commonly used research vehicles, so researchers should consider performing a brief HPLC stability assessment before committing to a multi-week oral gavage protocol.

Worked examples for research protocol planning

Example 1: In vitro GHSR1a activation assay. Stock solution preparation from one MK-677 10 mg tablet: Crush tablet, transfer powder to a 2 mL microcentrifuge tube. The molecular weight is 528.67 g/mol. To prepare a 10 mM stock: dissolve in 1.89 mL DMSO (10 mg ÷ 528.67 g/mol = 18.91 µmol; 18.91 µmol ÷ 10 mmol/L = 1.891 mL DMSO). Working concentrations for receptor activation assays: 1 nM, 10 nM, 100 nM, 1000 nM (1 µM). At EC50 approximately 1 nM, the 10 nM concentration provides approximately 10-fold the EC50 for a robust stimulated response.

Example 2: Rat in vivo 7-day body composition study. Protocol calls for 3 mg/kg/day oral gavage in 200 g male Wistar rats. Each animal receives 0.6 mg/day. Prepare a suspension at 0.3 mg/mL in 0.5% methylcellulose, gavage 2 mL per rat per day. A cohort of 10 rats over 7 days requires 10 x 0.6 mg x 7 = 42 mg total MK-677, equivalent to 4.2 tablets. Prepare suspension fresh each day from a pre-weighed crushed tablet aliquot to maintain dose consistency.

Example 3: Dose-response experiment in rat pituitary primary culture. Primary rat pituitary cells cultured at 500,000 cells/well in 24-well plates. DMSO stock at 10 mM diluted in DMEM to working concentrations: 0.1, 1, 10, 100, 1000 nM. Vehicle control: 0.01% DMSO. GH release into conditioned medium measured by ELISA at 30 and 60 minutes post-treatment. Expected result based on published literature: statistically significant GH release beginning at 1 nM, plateau near 10-100 nM, consistent with the receptor Km.

For general guidance on peptide and small-molecule reconstitution principles, see our reconstitution guide and dosage calculation guide.

Side Effects and Safety

Adverse event profile from controlled trials

The adverse events associated with MK-677 in controlled trials are largely predictable from its mechanism of action and can be grouped into GH/IGF-1-related effects and direct GHSR1a-mediated effects.

GH/IGF-1-related effects: The most consistently documented adverse events are increased appetite (reported in 60-80% of active-drug recipients in most trials), lower-extremity peripheral edema (20-40% at 25 mg/day), and muscle pain or transient myalgia (10-20%). ^[8] These reflect the direct anabolic and fluid-retentive properties of elevated GH/IGF-1. Peripheral edema results from GH-stimulated sodium and water retention at the renal tubule; it is typically mild, responsive to dose reduction, and resolves with discontinuation. Carpal tunnel syndrome symptoms have been reported in a minority of subjects, consistent with the known association between acromegaly and median nerve compression due to soft tissue oedema.

Metabolic effects: Fasting glucose increases of 5-15 mg/dL above baseline are a consistent finding across trials at 25 mg/day. Fasting insulin increases are proportionally larger, suggesting a decline in insulin sensitivity. ^[13] In the Nass et al. 2008 trial, HOMA-IR worsened significantly in the MK-677 group; this effect was more pronounced in subjects with baseline impaired fasting glucose. GH is a counter-regulatory hormone to insulin; chronic elevation by pharmacological means produces insulin resistance, which is a well-documented feature of both exogenous GH therapy and acromegaly. Researchers using MK-677 in metabolic research protocols must account for this potential confound.

Sleep-related effects: Sleep changes are generally reported as beneficial in subjective terms by trial participants (deeper, more restorative sleep), but polysomnographic changes may confound sleep architecture studies if MK-677 is used in protocols with sleep as an endpoint. ^[12]

Hepatotoxicity: Emerging case series data suggest a hepatocellular injury signal in unsupervised use contexts. ^[14] Whether this reflects the pharmacology of MK-677 itself, impurities in unregulated preparations, or drug-drug interactions cannot be definitively established from case series data, but the signal is sufficient to warrant monitoring of hepatic enzymes as a standard safety parameter in any in vivo research protocol using this compound.

Theoretical cancer risk: GH and IGF-1 signalling pathways are pro-proliferative, and sustained elevation of IGF-1 is associated epidemiologically with modestly increased risk of certain cancers (colorectal, breast, prostate) in observational data. ^[11] The controlled trials have not documented increased neoplasm rates in their observation windows (up to 2 years), and the absolute risk increase from 1-2 years of pharmacologically elevated IGF-1 in previously healthy adults is likely very small. Nevertheless, this consideration is relevant for researchers designing multi-year preclinical studies in cancer-prone animal models.

Tachyphylaxis and receptor desensitisation

In rats maintained on chronic MK-677, a progressive loss of GH secretory response has been documented over weeks of continuous dosing, associated with upregulation of hypothalamic somatostatin expression and potentially with GHSR1a downregulation at the level of somatotrophs. ^[10] Notably, this tachyphylaxis does not appear to occur in human trials, where GH and IGF-1 elevations are maintained over 12-24 months of daily dosing. ^[2] The discrepancy may reflect species differences in GHSR1a regulation, differences in dosing schedules (once-daily bolus in humans vs continuous infusion or multiple-daily-dose rodent protocols), or differences in hypothalamic-pituitary feedback dynamics between rats and humans. Researchers planning long-duration rodent studies should anticipate potential dose-response attenuation over time and design their protocols to include GH pulse sampling at multiple timepoints to detect any pharmacodynamic drift.

Open research questions in MK-677 safety

Several mechanistic safety questions remain unresolved in the published literature. First, the dose-duration relationship for insulin resistance has not been fully characterised: do glucose tolerance deficits resolve with longer-term treatment as the GH-IGF-1 axis adapts, or do they persist and worsen? The available human trial data do not extend beyond 24 months. Second, the significance of GHSR1a activation in cardiac tissue is not established for MK-677 specifically: is there a cardioprotective effect, a neutral effect, or a risk at supraphysiological doses? Third, the hepatotoxicity signal from case series needs prospective evaluation with pure compound and standardised liver function monitoring. Each of these represents a legitimate research question that could be addressed using the compound in appropriately designed preclinical protocols.

How It Compares

Comparative narrative

MK-677's most distinctive feature relative to the peptide secretagogues is its oral bioavailability. GHRP-2, GHRP-6, ipamorelin, and hexarelin are all administered subcutaneously or intravenously in research contexts because they are rapidly degraded in the gastrointestinal tract. The practical consequence for laboratory research is that oral gavage dosing, a lower-stress and higher-throughput route in rodent studies, is only feasible with MK-677 among the potent GHSR1a agonists currently available. For in vivo protocols where twice-daily injections would introduce significant handling stress and potential confounds, MK-677's oral route is a meaningful advantage.

Compared with ipamorelin, which is regarded as the most selectivity-optimised of the peptide secretagogues (no cortisol or prolactin release, minimal non-GHSR1a activity), MK-677 has a broadly similar GHSR1a pharmacology but adds the hepatic metabolism and extended duration of action. Ipamorelin produces a cleaner GH pulse with less appetite stimulation, which may be preferable in protocols where appetite confounds are problematic. MK-677's more pronounced appetite and orexigenic effects, mediated by direct GHSR1a activation in hypothalamic AgRP neurons, can themselves be a research target or a confounder depending on the study design.

Hexarelin is the highest-potency peptide GHSR1a agonist by receptor binding Ki, but its activity at CD36 and its cortisol-releasing effects limit its utility in protocols targeting clean GH-axis effects. GHRP-6 has the most pronounced appetite/orexigenic effect among the peptides, driven by its strong ghrelin-like activity, and is a useful research tool for appetite biology but less specific for studying GH secretion in isolation.

The GHRH analogues CJC-1295 and sermorelin operate through a completely different receptor (GHRHR, not GHSR1a) and produce GH release by amplifying the physiological GHRH signal rather than by mimicking ghrelin. Combining a GHRH analogue with a GHSR1a agonist like MK-677 produces synergistic GH release in animal models, a combination investigated in several preclinical protocols. For mechanistic dissection of GHSR1a vs GHRHR pathways, using MK-677 alone versus a GHRH analogue alone versus the combination provides a tractable experimental framework.

From a human evidence perspective, MK-677's multi-year Phase II/III dataset remains unmatched in the secretagogue space. No other compound in this category has been studied in randomised controlled trials exceeding 12 months, except for the ongoing LUM-201 programme, which uses the same chemical entity. This depth of clinical evidence base, while not guaranteeing safety or efficacy in unsupervised use contexts, does provide researchers with better-defined pharmacodynamic benchmarks and adverse event profiles than are available for any of the peptide alternatives.

Where to Buy

Apollo Peptide Sciences is the vendor for this MK-677 product. Detailed supply information, current pricing, lot-specific CoA links, and the affiliate purchase path are available on our MK-677 Ibutamoren product page. Researchers comparing vendors across the GH-secretagogue category should consult our comprehensive supplier evaluation guide, which covers CoA documentation standards, third-party testing practice, shipping and handling conditions, and customer service quality metrics for currently active research-peptide suppliers.

When evaluating competing sources for MK-677 specifically, the critical procurement considerations are: (1) confirmation that HPLC purity assessment used a small-molecule analytical method appropriate for MK-677, not a peptide method; (2) availability of mass spectrometry identity confirmation with the correct m/z; (3) tablet weight uniformity data for tablet formulations; and (4) documentation of the excipient composition, which affects dissolution rate and may matter for in vitro dissolution studies. Apollo Peptide Sciences provides CoA documentation consistent with these requirements for the MK-677 10mg tablet product.

Researchers should also confirm that their institution's procurement and compliance policies permit purchase and possession of investigational compounds for non-clinical research purposes. Requirements vary substantially by jurisdiction and institutional policy. See our disclaimer for the legal framework under which research-peptide purchases are conducted.

Pharmacological Context: GH Axis Biology and Research Relevance

Understanding the pharmacological context for MK-677 requires a working knowledge of GH axis regulation, which is considerably more complex than a simple stimulus-response model. GH secretion from anterior pituitary somatotrophs is governed by the interplay of three primary regulatory inputs: stimulatory signals from GHRH (hypothalamic), stimulatory signals from ghrelin/GHSR1a agonists (hypothalamic and pituitary), and inhibitory signals from somatostatin (hypothalamic). These signals integrate at multiple levels, and the pulsatile nature of normal GH secretion reflects the oscillatory dynamics of somatostatin release, which creates alternating windows of GH responsiveness. ^[15]

MK-677 exploits this regulatory architecture by simultaneously enhancing pituitary somatotroph responsiveness (via direct GHSR1a activation) and reducing somatostatin tone (via GHSR1a on hypothalamic interneurons), resulting in GH pulses of increased amplitude with largely preserved frequency. This pattern differs meaningfully from exogenous GH administration, which produces a continuous non-pulsatile elevation that rapidly desensitises the GH receptor through receptor downregulation and STAT5 pathway attenuation. The preservation of pulsatile GH dynamics by MK-677 likely explains why GH receptor downregulation is less pronounced with MK-677 than with exogenous GH replacement, and may underlie the more durable IGF-1 elevations seen with daily MK-677 compared with the receptor attenuation observed in some continuous exogenous GH protocols. ^[11]

GH itself exerts both direct and IGF-1-mediated actions. Direct GH effects include lipolysis in adipose tissue, counter-regulatory insulin antagonism in the liver and muscle, and protein synthesis stimulation. IGF-1-mediated effects include the majority of growth-promoting, anabolic, and bone-remodelling actions. In older adults, the GH/IGF-1 axis undergoes a well-characterised decline termed the somatopause: pulse amplitude falls, 24-hour GH area under the curve decreases, and IGF-1 levels drop into a range associated with reduced muscle mass, increased adiposity, and decreased bone density. ^[2] MK-677's ability to restore GH and IGF-1 toward younger-adult levels in this population is the primary rationale for the body composition and bone density studies described in the research evidence section.

The appetite effects of MK-677, mediated independently of the GH axis via GHSR1a on arcuate nucleus AgRP/NPY neurons, are not a side effect in a strict mechanistic sense but are an intrinsic pharmacological property of GHSR1a activation. Ghrelin is the primary hormonal appetite signal in the fasting state, and MK-677 as a full GHSR1a agonist activates this pathway robustly. ^[6] This creates a pharmacological scenario where the same compound simultaneously promotes anabolic GH/IGF-1 signalling and increases caloric intake drive, which are synergistic for muscle mass accretion but potentially problematic for fat mass management. The net body composition outcome in most trials, modest lean mass gain with variable fat mass changes, reflects this dual action.

Open Research Questions

Several areas in MK-677 pharmacology remain genuinely unresolved in the published literature, representing legitimate opportunities for laboratory investigation.

Optimal dosing schedule: All pivotal human trials used once-daily oral dosing. Whether intermittent dosing (e.g., 5 days on, 2 days off) or pulsed dosing designed to mimic natural GH pulse timing would produce equivalent IGF-1 elevation with reduced metabolic side effects has not been formally tested. Preclinical rodent data on this question are limited.

Central nervous system effects: GHSR1a is expressed in multiple brain regions implicated in memory, mood, and stress responses. Ghrelin and GHSR1a agonists have shown anxiolytic and pro-cognitive effects in rodent models, but these effects have not been rigorously characterised for MK-677 specifically. Given the compound's oral bioavailability and CNS penetrance, it is a tractable tool for studying GHSR1a's role in hippocampal neurogenesis, spatial memory, and stress-axis regulation.

Sex differences in pharmacodynamic response: Most MK-677 trial analyses have included both sexes but have not adequately powered subgroup analyses for sex differences in GH/IGF-1 response or metabolic effects. Women's GH secretion is estrogen-regulated in complex ways, and estrogen affects IGF-1 binding protein profiles, which could alter free IGF-1 elevation. Whether postmenopausal women respond differently from men of equivalent age is unclear from available data.

Interactions with caloric restriction or intermittent fasting: Ghrelin rises in fasting states, and GHSR1a agonism in a caloric-deficit context may produce different body composition outcomes than in eucaloric contexts. This question has practical relevance for aging and longevity research models but has not been directly addressed in published MK-677 trials.

Long-term insulin resistance trajectory: The available trial data show insulin sensitivity declines at 6-12 months. Whether this plateau, worsens, or reverses with longer-term treatment is unknown. Animal models addressing the 18-24 month insulin sensitivity trajectory under chronic GHSR1a agonism would be informative.

FAQ